NewsLatest news and press releases

June 25, 2022

Antios Therapeutics’ ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study

New data presented in two separate oral presentations at the European Association for the Study of the Liver’s International Liver Congress 2022 (EASL ILC 2022) Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated with alanine aminotransferase (ALT) normalization and no ALT flares off-treatment Antios’ capsid assembly modulators […]

June 8, 2022

Antios Therapeutics Announces Oral Presentations on ATI-2173, ATI-1428, and ATI-1645 Hepatitis B Virus Programs at the EASL International Liver Congress™ 2022

DOYLESTOWN, P.A., June 8, 2022 – Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceutical company developing innovative therapies to advance treatments that can provide a bridge to a cure for chronic hepatitis B virus (HBV), today announced the acceptance of oral presentations highlighting ATI-2173, Antios’ lead therapeutic HBV candidate and the only Active Site Polymerase Inhibitor […]

April 26, 2022

Antios Therapeutics Announces Notice of Allowance for U.S. Patent on Phosphoramidates for the Treatment of Hepatitis B Virus

DOYLESTOWN, PA, April 26, 2022 – Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 16/312,756, titled, “Phosphoramidates for the Treatment of […]

March 30, 2022

Antios Therapeutics’ ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies

ATI-2173 demonstrated potent hepatitis B virus (HBV) DNA suppression ATI-2173, in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated with alanine aminotransferase (ALT) normalization and no safety signals DOYLESTOWN, P.A., March 30, 2022 – Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), […]

December 14, 2021

Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection

MENDHAM, N.J. and WARMINSTER, Pa., December 14, 2021 – Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A single cohort in the ongoing Antios Phase 2a SAVE-1 (Sustained Anti-Viral Efficacy) […]

Filter content
1 2 3 6

Improving lives through the treatment of HBV About our therapies